Blog
RSS FeedPosted by Michael Wonder on 19 Aug 2022
1 September 2022 updates as part of the digital transformation of authority required (written) PBS listings
19 August 2022 - From 1 September 2022, the PBS listings for certain cancer medicines will be updated as part of ...
Posted by Michael Wonder on 19 Aug 2022
Aeglea BioTherapeutics announces European Medicines Agency validation of marketing authorisation application for pegzilarginase for the treatment of arginase 1 deficiency
18 August 2022 - Aeglea BioTherapeutics today announced that a marketing authorisation application for pegzilarginase for the treatment of arginase 1 ...
Posted by Michael Wonder on 18 Aug 2022
Stability of changes in health status: next step in comprehensively assessing patient reported outcomes
18 August 2022 - Chronic diseases can impair patients’ health status due to symptoms, functional limitations, and impaired quality of life. ...
Posted by Michael Wonder on 18 Aug 2022
Canadians seek diabetes medication as replacement for weight loss drug during arrival delays
18 August 2022 - High demand in the United States for a new weight-loss medication has indefinitely delayed its arrival ...
Posted by Michael Wonder on 18 Aug 2022
AARP Pennsylvania convenes discussion on lower prescription drug costs after Inflation Reduction Act signed into law
18 August 2022 - Senator Bob Casey joins AARP Discussion. ...
Posted by Michael Wonder on 18 Aug 2022
Caps on prescription drug price hikes most popular aspect of Inflation Reduction Act: poll
18 August 2022 - A cap on prescription drug price increases is the most popular part of the Inflation Reduction ...
Posted by Michael Wonder on 18 Aug 2022
CSL Vifor plans UK launch after NICE backs rare disease drug Tavneos
18 August 2022 - UK cost-effectiveness organisation NICE has recommended routine NHS use of a recently approved therapy for two ...
Posted by Michael Wonder on 18 Aug 2022
Chiesi’s Trimbow recommended for use within NHS Scotland
18 August 2022 - The SMC approval brings much needed boost to asthma sufferers across Scotland. ...
Posted by Michael Wonder on 18 Aug 2022
Restart of National Medicines Policy Review is welcome, but assurances needed over further consultation and feedback processes
18 August 2022 - Medicines Australia welcomes the restart of the National Medicines Policy Review, which was put on hold ...
Posted by Michael Wonder on 18 Aug 2022
FDA label update reflects Bayer’s commitment to providing options for long-acting contraception
18 August 2022 - FDA approves extension of Mirena (levonorgestrel-releasing intrauterine system) 52 mg intrauterine device for up to eight years ...
Posted by Michael Wonder on 18 Aug 2022
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
18 August 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 18 Aug 2022
U.S. FDA accepts Astellas' new drug application for fezolinetant
18 August 2022 - If approved by the FDA, fezolinetant would be a non-hormonal treatment for moderate to severe vasomotor ...
Posted by Michael Wonder on 18 Aug 2022
PHARMAC makes cancer treatment available to more people
18 August 2022 - PHARMAC has confirmed today they are widening access from 1 September 2022 to a targeted cancer treatment, ...
Posted by Michael Wonder on 17 Aug 2022
Early phase oncology trials: why so many designs?
12 August 2022 - The past 30 years have seen a considerable effort on the part of statisticians to improve the ...
Posted by Michael Wonder on 17 Aug 2022
Accelerated approval of cancer drugs: no economic reward for drug makers that conduct confirmatory trials
17 August 2022 - The FDA uses expedited approval of drugs to speed the development and assessment of drugs that address ...